# Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

> **NCT04882241** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 120 (actual)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Placebo
- **DRUG:** Cisplatin
- **DRUG:** Capecitabine
- **DRUG:** 5-fluorouracil
- **DRUG:** Docetaxel
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin

## Key facts

- **NCT ID:** NCT04882241
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-29
- **Primary completion:** 2024-02-16
- **Final completion:** 2025-04-23
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04882241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04882241, "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04882241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*